Rare CNS Tumors Outcomes &Risk

Suspended

• Conditions: High Grade Meningioma; Ependymoma; Medulloblastoma; PNET; Primary CNS Sarcoma

• Registration Number: NCT03251989
• Lead Sponsor: National Cancer Institute (NCI)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-8-15
• Last Update Posted: 23 September 2024

Recruitment & Eligibility

• Status: Suspended
• Sex: All
• Target Recruitment: 326

Inclusion Criteria

INCLUSION CRITERIA:<br><br>Participants with rare CNS tumors who meet the following criteria will be invited to<br>participate in the study:<br><br> - A diagnosis of rare CNS tumors, (Atypical teratoid rhabdoid tumor (ATRT); Brainstem<br> and midline gliomas; Choroid plexus tumors; Ependymoma; High grade meningioma;<br> Gliomatosis cerebri; Medulloblastoma; Oligodendroglioma / Anaplastic<br> oligodendroglioma; Pineal region tumors; Pleomorphic xanthroastrocytoma / Anaplastic<br> pleomorphic xanthroastrocytoma; PNET (Supratentorial embryonal tumor); Primary CNS<br> sarcoma / Secondary CNS sarcoma (Gliosarcoma) or as reported by the participant<br><br> - Ability to speak, write, and read English, as questionnaires available in English<br> language only.<br><br> - Ability of participant to understand and the willingness to sign a written informed<br> consent document.<br><br>EXCLUSION CRITERIA: See inclusion criteria

Exclusion Criteria

Not provided

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Relationship between health status and disease and treatment characteristics as well as clinical and demographic risk factors as self reported by adult participants with rare CNS tumors; and the relationship of genomic susceptibility of the popu...